CN114751927B - 一种硼酸化合物、制备方法及用途 - Google Patents
一种硼酸化合物、制备方法及用途 Download PDFInfo
- Publication number
- CN114751927B CN114751927B CN202210228962.7A CN202210228962A CN114751927B CN 114751927 B CN114751927 B CN 114751927B CN 202210228962 A CN202210228962 A CN 202210228962A CN 114751927 B CN114751927 B CN 114751927B
- Authority
- CN
- China
- Prior art keywords
- compound
- stat3
- formula
- boric acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Boric acid compound Chemical class 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000004327 boric acid Substances 0.000 title claims abstract description 34
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims abstract description 60
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims abstract description 60
- 230000000694 effects Effects 0.000 claims abstract description 34
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 30
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 238000006482 condensation reaction Methods 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 42
- 230000027455 binding Effects 0.000 abstract description 13
- 230000026731 phosphorylation Effects 0.000 abstract description 10
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 10
- 230000007246 mechanism Effects 0.000 abstract description 7
- 108020004414 DNA Proteins 0.000 abstract description 4
- 239000000539 dimer Substances 0.000 abstract description 4
- 230000002018 overexpression Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 91
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 89
- 229940125904 compound 1 Drugs 0.000 description 66
- 206010017758 gastric cancer Diseases 0.000 description 39
- 201000011549 stomach cancer Diseases 0.000 description 39
- VFPYGNNOSJWBHF-UHFFFAOYSA-N 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]benzoic acid Chemical compound FC=1C(F)=C(F)C(F)=C(F)C=1S(=O)(=O)N(C)CC(=O)N(C=1C=CC(=CC=1)C(O)=O)CC(C=C1)=CC=C1C1CCCCC1 VFPYGNNOSJWBHF-UHFFFAOYSA-N 0.000 description 38
- 239000007787 solid Substances 0.000 description 31
- 239000003153 chemical reaction reagent Substances 0.000 description 28
- 239000002994 raw material Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000006907 apoptotic process Effects 0.000 description 14
- RHIGOXBTMPLABF-UHFFFAOYSA-N 3-(4-cyanophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(C#N)C=C1 RHIGOXBTMPLABF-UHFFFAOYSA-N 0.000 description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- 230000009545 invasion Effects 0.000 description 12
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000003698 anagen phase Effects 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 108010052090 Renilla Luciferases Proteins 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000012192 staining solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- UOJCTEGNHXRPKO-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzenesulfonyl chloride Chemical compound FC1=C(F)C(F)=C(S(Cl)(=O)=O)C(F)=C1F UOJCTEGNHXRPKO-UHFFFAOYSA-N 0.000 description 3
- YMXIIVIQLHYKOT-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(N)=C1 YMXIIVIQLHYKOT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 102000055104 bcl-X Human genes 0.000 description 3
- 108700000711 bcl-X Proteins 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- GWLOGZRVYXAHRE-UHFFFAOYSA-N n,4-dimethylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(C)C=C1 GWLOGZRVYXAHRE-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000005758 transcription activity Effects 0.000 description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- XVFZFBSJOOIKIK-UHFFFAOYSA-N 1-(bromomethyl)-4-cyclohexylbenzene Chemical compound C1=CC(CBr)=CC=C1C1CCCCC1 XVFZFBSJOOIKIK-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- RYAQFHLUEMJOMF-UHFFFAOYSA-N 4-phenoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=CC=C1 RYAQFHLUEMJOMF-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- JWJVSDZKYYXDDN-ZCFIWIBFSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@@H]1C(O)=O JWJVSDZKYYXDDN-ZCFIWIBFSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- ZAWXOCUFQSQDJS-VIFPVBQESA-N (3s)-8-hydroxy-3-methyl-3,4-dihydro-2h-benzo[a]anthracene-1,7,12-trione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C=CC1=C2C(=O)C[C@@H](C)C1 ZAWXOCUFQSQDJS-VIFPVBQESA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- DLIXOJOZPKXZQH-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F DLIXOJOZPKXZQH-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- IXOFPUCWZCAFJX-UHFFFAOYSA-N 2-phenylethanethioic s-acid Chemical compound SC(=O)CC1=CC=CC=C1 IXOFPUCWZCAFJX-UHFFFAOYSA-N 0.000 description 1
- FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 1
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 description 1
- QCIWHVKGVVQHIY-UHFFFAOYSA-N 4-cyclohexylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CCCCC1 QCIWHVKGVVQHIY-UHFFFAOYSA-N 0.000 description 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 238000012406 Annexin V-FITC/PI double staining Methods 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZTOVOOWZKPUDSZ-JOCHJYFZSA-N OB(C(C=C1)=CC=C1N(CC1=CC=C(C2CCCCC2)C=C1)C([C@@H](CC1)N1S(C(C(F)=C(C(F)=C1F)F)=C1F)(=O)=O)=O)O Chemical compound OB(C(C=C1)=CC=C1N(CC1=CC=C(C2CCCCC2)C=C1)C([C@@H](CC1)N1S(C(C(F)=C(C(F)=C1F)F)=C1F)(=O)=O)=O)O ZTOVOOWZKPUDSZ-JOCHJYFZSA-N 0.000 description 1
- OXUCXHVGAXTWFQ-HSZRJFAPSA-N OB(C(C=C1)=CC=C1N(CC1=CC=C(C2CCCCC2)C=C1)C([C@@H](CCC1)N1S(C(C(F)=C(C(F)=C1F)F)=C1F)(=O)=O)=O)O Chemical compound OB(C(C=C1)=CC=C1N(CC1=CC=C(C2CCCCC2)C=C1)C([C@@H](CCC1)N1S(C(C(F)=C(C(F)=C1F)F)=C1F)(=O)=O)=O)O OXUCXHVGAXTWFQ-HSZRJFAPSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- KAEGGIFPLJZUOZ-UHFFFAOYSA-N Renilla luciferin Chemical compound C1=CC(O)=CC=C1C(N1)=CN2C(=O)C(CC=3C=CC=CC=3)=NC2=C1CC1=CC=CC=C1 KAEGGIFPLJZUOZ-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- UFCZCJYLUGMEJH-UHFFFAOYSA-N dodecanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCCCCCCCCCC(O)=O UFCZCJYLUGMEJH-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000009950 gastric cancer growth Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种硼酸化合物、制备方法及用途。该硼酸化合物具有如式(Ⅰ)所示结构:本发明提供的硼酸化合物对STAT3蛋白具有高活性,通过抑制STAT3磷酸化、STAT3二聚体与DNA的结合等机制显著抑制STAT3过表达的细胞活性,且化合物与STAT3靶点的结合力高,可以选择性的抑制STAT3。
Description
技术领域
本发明涉及药物化学和药物治疗学领域,特别涉及一种硼酸化合物、制备方法及用途。
背景技术
信号转导与转录激活因子3(STAT3)是一类具有信号转导和转录激活的双功能蛋白,负责调控细胞的生长、增值、分化以及凋亡等一系列重要生理过程。研究发现STAT3持续性激活及异常高表达,能够诱导细胞增殖、侵袭、迁移,抑制细胞凋亡,促进血管生成,在肿瘤的发生发展转移过程中发挥重要的作用。
其中,SH2结构域对STAT3的激活起着至关重要的作用,它能特异性识别磷酸化酪氨酸残基,从而被磷酸化激活。磷酸化后的STAT3迅速进入细胞核,由单体形成同源或异源二聚体从而作为转录因子,与靶基因的启动子结合,激活转录。由于SH2结构域选择性地与磷酸化酪氨酸(PTyr)肽结合,介导与癌症、炎症、过敏等疾病有关的细胞信号通路,因此开发特异性STAT3抑制剂来破坏pTyr-SH2相互作用是肿瘤治疗领域中的一个研究热点。
迄今为止,已有数个靶向STAT3候选药物进入I/II期临床试验(Eur J MedChem.2020Feb1;187:111922.),如:S31-201、SF-1-066、STA-21、LLL-3、BP-1-102和SH-4-54,但多数化合物的亲水能力强、膜通透性差,在较高浓度下(IC50>10μmol·L-1)才能对STAT3高表达肿瘤细胞株的增殖产生抑制作用,因此需进一步的结构优化提高成药性。
综上所述,靶向STAT3的特异性抑制剂已经成为研发的热点,但现今为止已研发的药物,都存在膜通透性差、药效作用小、成药性差等缺点,限制了STAT3抑制剂的临床应用与后期开发。而STAT3作为一个具有前景的肿瘤治疗靶点,本领域迫切需要开发新的一类化合物,能特异性的抑制STAT3,具有选择性高、药效强、成药性好等特征。
发明内容
本发明的目的在于克服现有靶向STAT3候选药物存在的缺陷或不足,提供一种硼酸化合物。本发明提供的硼酸化合物对STAT3蛋白具有高活性,通过抑制STAT3磷酸化、STAT3二聚体与DNA的结合等机制显著抑制STAT3过表达的细胞活性,且化合物与STAT3靶点的结合力高,可以选择性的抑制STAT3。
本发明的另一目的在于提供上述硼酸化合物的制备方法。
本发明的另一目的在于提供上述硼酸化合物在制备抑制STAT3活性的药物中的用途。
本发明的另一目的在于提供上述硼酸化合物在制备预防和/或***或癌症的药物中的用途。
为了实现本发明的上述目的,本发明提供了如下技术方案:
一种硼酸化合物,具有如式(Ⅰ)所示结构:
其中,n为0~2的整数;
t=0~1的整数;
X、Y独立地选自CH或N;
R1选自一个或多个氢、卤素、羟基、氨基、硝基、氰基、三氟甲基、C1-C6烷基、C1-C6烷氧基、-C(O)Ra、-OC(O)Ra、-NRaRb、-CO2Ra或-CONHRa;
R2选自氢、取代或非取代C3-C6环烷基、取代或非取代C3-C6杂环烷基、取代或非取代芳基、取代或非取代5-10元杂环芳基;
R3选自芳基、5-10元杂环芳基、C5-C10桥环基、C5-C10稠环基、C1-C6烷基或C3-C6杂环烷基;
Ra、Rb独立地选自氢或C1-C6烷基,或Ra、Rb形成C3-C6环烷基。
本发明以苯硼酸作为成药骨架,能够模拟磷酸化,具备成药性等特征,并进行特定取代后得到的硼酸化合物对STAT3蛋白具有高活性,通过抑制STAT3磷酸化、STAT3二聚体与DNA的结合等机制显著抑制STAT3过表达的细胞活性,且化合物与STAT3靶点的结合力高,可以选择性的抑制STAT3。
优选地,n为0或1。
优选地,t为1。
优选地,X为CH。
优选地,Y为CH。
优选地,R1为氢。
优选地,所述R2中取代基为卤素、羟基、氨基、硝基、氰基、三氟甲基、芳基、杂环芳基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C1-C6烷氧基、C1-C6烷氨基、C3-C7环烯基、C3-C6杂环烷基、C3-C7饱和杂环、-COORa或-CONHRa;或R2中芳基或5-10元杂环芳基与取代基形成萘基、吲哚基、苯并呋喃或苯并噻吩基。
更为优选地,所述R2中取代基为芳基(例如苯基、萘基、吲哚基、苯并呋喃或苯并噻吩基,本发明中的芳基均可按此理解),取代基的数量为1个。
优选地,R2为氢、芳基(例如苯基、萘基、吲哚基、苯并呋喃或苯并噻吩基)或5-6元杂环芳基。
优选地,所述R3中取代基为卤素、羟基、氨基、硝基、氰基、三氟甲基、三氟甲氧基、芳基氧基、芳基巯基、芳基胺基、芳基、杂芳基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C1-C6烷氧基、C1-C6烷氨基、C3-C7环烯基、C3-C6杂环烷基、C3-C7饱和杂环、C5-C10桥环基、-CO2Ra、-CONHRa或-RaNRbSO2Rc,Rc为三氟甲基、取代或非取代芳基,或取代或非取代杂环芳基。
更为优选地,所述R3中取代基的数量为1~5个。
更为优选地,所述R3中取代基为-RaNRbSO2Rc。
更为优选地,Rc中取代芳基、取代杂环芳基中的取代基独立地选自C1-C6烷基、卤素、羟基、氰基或三氟甲基,取代基的数量为1~5个。
优选地,所述硼酸化合物具有如下编号所示结构:
上述硼酸化合物的制备方法,包括如下步骤:
S1:将式(1)所示相应的胺和式(2)所示相应的酸溶于溶剂中,经缩合反应后生成式(3)所示中间体;
S2:式(3)所示中间体与式(4)所示物质在碱性条件下经取代反应得到式(5)所示中间体;
S3:式(5)所示中间体在酸性条件下水解,即得式(Ⅰ)所示硼酸化合物。
反应过程如下:
优选地,S1中所述溶剂为N,N-二甲基甲酰胺、丙酮、四氢呋喃、二氯甲烷、乙腈或水中的一种或几种。
优选地,S1中所述缩合反应和水解反应的反应温度为室温;所述取代反应的反应温度为0~25℃。
优选地,S1中所述缩合反应中式(1)所示相应的胺和式(2)所示相应的酸的摩尔比为1:(1.2~1.5)。
优选地,S2中所述碱为N,N-二异丙基乙胺、碳酸铯、氢化钠或三乙胺的一种或几种。
优选地,S2中所述取代反应中式(3)所示中间体和式(4)所示物质的摩尔比为1:(1.0~1.5)。
优选地,S3中所述酸为盐酸。
优选的,当R2为氢,n为0时,所述硼酸化合物通过如下过程制备得到:将式(1)所示相应的胺和式(2)所示相应的酸溶于溶剂中,经缩合反应后生成式(6)所示中间体;式(6)所示中间体在酸性条件下水解生成式(Ⅰ)所示硼酸化合物。
反应过程如下:
优选地,当R3为-RaNRbSO2Rc时,所述硼酸化合物通过如下过程制备得到:
将式(1)所示相应的胺和式(7)所示相应的酸溶于溶剂中,经缩合反应后生成式(8)所示中间体;
式(8)所示中间体与式(4)所示物质在碱性条件下经取代反应得到式(9)所示中间体;
式(9)所示中间体在酸性条件下去除保护基,然后在碱性条件下与相应的酰氯发生酰化反应得到式(10)所示中间体;
式(10)中间体在酸性条件下水解生成式(Ⅰ)所示硼酸化合物。
反应过程如下:
优选地,所述酰化反应和水解反应的反应温度为室温
优选地,所述酰化反应中式(9)所示物质和相应的酰氯的摩尔比为1:(1.0~1.1)。
上述硼酸化合物及其药学可接受的盐、代谢物或前药在制备抑制STAT3活性的药物中的用途也在本发明的保护范围内。
优选地,药学可接受的盐为药学上可接受的酸加成盐,即通过酸处理形成的药学上可接受的盐。
所述酸为药学上可接受的无机酸和药学上可接受的有机酸;所述的酸加成盐为盐酸盐、氢溴酸盐、硝酸盐、甲基硝酸盐、硫酸盐、硫酸氢盐、氨基硫酸盐、磷酸盐、乙酸盐、羟基乙酸盐、苯基乙酸盐、丙酸盐、丁酸盐、异丁酸盐、戊酸盐、马来酸盐、羟基马来酸盐、丙烯酸盐、延胡索酸盐、苹果酸盐、酒石酸盐、柠檬酸盐、水杨酸盐、对氨基水杨酸盐、乙醇酸盐、乳酸盐、庚酸盐、邻苯二甲酸盐、草酸盐、琥珀酸盐、苯甲酸盐、邻乙酰氧基苯甲酸盐、氯苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、羟苯酸盐、甲氧基苯甲酸盐、扁桃酸盐、丹宁酸盐、甲酸盐、硬脂酸盐、抗坏血酸盐、棕榈酸盐、油酸盐、丙酮酸盐、双羟奈酸盐、丙二酸盐、月桂酸盐、戊二酸盐、谷氨酸盐、丙酸酯月桂硫酸盐(estolate)、甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、对氨基苯磺酸盐、对甲苯磺酸盐(甲苯磺酸盐)和萘-2-磺酸盐等。
优选地,所述硼酸化合物及其药学可接受的盐、代谢物或前药在制备治疗STAT3高表达的细胞异常增殖、形态变化以及运动功能亢进等相关的疾病中的用途。
上述硼酸化合物及其药学可接受的盐、代谢物或前药在制备预防和/或***的药物中的用途。
研究表明,该硼酸化合物可抑制癌细胞增殖、生存、迁移和侵袭并促进其凋亡,具有制备预防和/或***或癌症的药物中的用途。
优选地,所述硼酸化合物及其药学可接受的盐、代谢物或前药在制备预防和/或治疗癌症的药物中的用途。
更为优选地,所述癌症为肺癌、骨癌、胃癌、胰腺癌、皮肤癌、头颈癌、子宫癌、卵巢癌、睾丸癌、输卵管癌、子宫内膜癌、子***、***癌、脑癌、垂体腺瘤、表皮样癌、T细胞淋巴瘤、慢性和急性白血病、大肠癌、肾癌、食道癌、***癌、***、膀胱癌、纤维肉瘤、乳腺癌、食道癌、膀胱癌、造血***癌、淋巴瘤、髓母细胞瘤、成神经管细胞瘤、直肠腺癌、结肠癌、肝癌、腺样囊性癌、***癌、头颈部鳞状细胞癌、脑癌、肝细胞癌、黑色素瘤、少突神经胶质瘤、胶质母细胞癌、卵巢透明细胞癌、卵巢浆液性囊腺癌、甲状腺癌、多发性骨髓瘤(AML)、套细胞淋巴瘤、三阴性乳腺癌、非小细胞肺癌等。
相对于现有技术,本发明具有如下的优点及效果:
本发明提供的硼酸化合物对STAT3蛋白具有高活性,通过抑制STAT3磷酸化、STAT3二聚体与DNA的结合等机制显著抑制STAT3过表达的细胞活性,且化合物与STAT3靶点的结合力高,可以选择性的抑制STAT3。
附图说明
图1为化合物1对胃癌细胞克隆形成的影响结果图,其中图1(A)为化合物1抑制AGS细胞的克隆形成及抑制MGC803细胞的生长图,图1(B)为图1(A)的统计学结果;
图2为化合物1抑制胃癌细胞的迁移结果图,其中图2(A)为划痕实验检测化合物对胃癌细胞迁移的影响结果图;图2(B)为图2(A)的统计学结果;
图3为化合物1在不同浓度下侵袭细胞图,图3(A)为显微镜拍照下化合物1不同浓度下侵袭细胞图;图3(B)为图3(A)的统计结果图;
图4为化合物1进胃癌细胞凋亡结果图,图4(A)为利用流式细胞仪检测胃癌细胞凋亡的情况图,图4(B)为图4(A)的统计学结果;
图5为化合物1与STAT3蛋白结合结果图,图5(A)为SPR结果,图5(B)为CESTA结果;
图6为化合物1抑制pY705-STAT3的磷酸化及下游基因的表达结果图;
图7为化合物1抑制STAT3的转录活性结果图;
图8为化合物1抑制STAT3二聚化结果图;
图9为化合物1抑制肿瘤生长结果图;其中,图(9A)为经化合物1和对照化合物SH-4-54治疗21天后的小鼠肿瘤图;图(9B)为肿瘤的生长曲线图;图(9C)为重点肿瘤重量统计图;图(9D)为Western Blot试验结果图;图(9E)为小鼠重量生长统计图;图(9F)为化合物1和SH-454对主要脏器形态影响图。
具体实施方式
以下结合实施例和附图进一步解释本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明,本发明所用试剂和材料均为市购。
实施例1
(4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲基苯基)磺酰氨基)乙酰氨基)苯基)硼酸
具体制备过程为:
步骤1:制备叔丁基甲基(2-氧代-2-((4-(4,4,5,5-四甲基-1,3,2-二氧苯并呋喃-2-基)苯基)氨基)乙基)氨基甲酸酯(1a)
将4-氨基苯硼酸频哪醇酯(4.0g,18.26mmol)、叔丁氧羰酰基肌氨酸(4.16g,21.91mmol)、HATU(8.33g,21.91mmol)和N,N-二异丙基乙胺(9.5ml,54.78mmol)溶于适量的N,N-二甲基甲酰胺中,室温搅拌过夜。反应完成,乙酸乙酯以及水萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体4.27g,产率为60%。1H NMR(400MHz,CDCl3)δ7.77(d,J=8.1Hz,2H),7.51(d,J=8.2Hz,2H),3.96(s,2H),3.01(s,3H),1.49(s,9H),1.33(s,12H).LCMS:m/z(M+H+):390.23.
步骤2:制备叔丁基(2-((4-环己基苄基)(4-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯基)氨基)-2-氧乙基(甲基)氨基甲酸酯(1b)
取氢化钠(1.23g,30.75mmol),加入适量的超干四氢呋喃,冰浴条件下缓慢加入化合物1a(4.0g,10.25mmol),搅拌1h后,加入4-环己基苄溴(2.6g,10.25mmol),室温搅拌过夜。反应完成后,加水淬灭,乙酸乙酯萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体4.09g,产率为70%。1H NMR(400MHz,CDCl3)δ7.77(dd,J=12.5,8.0Hz,2H),7.10(dd,J=14.2,6.8Hz,4H),7.06–6.92(m,2H),4.82(d,J=5.5Hz,2H),3.64(d,J=52.1Hz,2H),2.88(d,J=12.5Hz,3H),2.45(s,1H),1.78(dd,J=41.3,12.0Hz,6H),1.44(s,4H),1.40(d,J=18.5Hz,9H),1.33(t,J=5.0Hz,12H).LCMS:m/z(M+H+):562.36.
步骤3:制备N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲基苯基)磺酰胺)-N-(4-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯基)乙酰胺(1c)
取化合物1b(3.5g,6.22mmol),加入适量的二氯甲烷溶解,冰浴条件下加入三氟乙酸(4.6ml,62.24mmol),搅拌1小时。反应完全后,乙酸乙酯萃取,旋干,用适量乙腈溶解,加入N,N-二异丙基乙胺(2.3ml,31.12mmol)、五氟苯磺酰氯(1.02ml,6.85mmol),室温搅拌。反应完成后,乙酸乙酯萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体1.91g,产率为62%。1H NMR(400MHz,DMSO)δ7.69(d,J=7.7Hz,2H),7.19(d,J=8.2Hz,2H),7.11(d,J=7.9Hz,2H),7.01(d,J=7.6Hz,2H),4.75(s,2H),3.98(s,2H),2.99(s,3H),2.44(s,1H),1.78–1.66(m,5H),1.35(dd,J=21.2,9.7Hz,5H),1.28(s,12H).LCMS:m/z(M+H+):692.25.
步骤4:制备(4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲基苯基)磺酰氨基)乙酰氨基)苯基)硼酸
取化合物1c(1.9g,2.74mmol),加入适量的四氢呋喃和水溶解,加入高碘酸钠(1.76g,8.23mmol)和2ml 2M稀盐酸溶液,室温搅拌。反应完成后,用乙酸乙酯萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体1.59g,产率为95.5%。1H NMR(400MHz,DMSO)δ7.85(dd,J=25.2,7.6Hz,2H),7.17–7.06(m,4H),7.01(d,J=7.3Hz,2H),4.74(s,2H),4.01(s,2H),3.02(s,3H),2.48–2.40(m,1H),1.71(dd,J=29.9,10.5Hz,5H),1.38–1.19(m,5H).HRMS(ESI)calcd for C28H28N2O5BF5S(M+H+):611.1810;found 611.1808.
实施例2
(R)-(4-(N-(4-环己基苄基)-1-((五氟苯基)磺酰基)吡咯烷-2-甲酰胺基)苯基)硼酸
步骤:将叔丁氧羰酰基肌氨酸换成Boc-D-脯氨酸, 其余所需原料、试剂以及制备方法同实施例1,得白色固体。1H NMR(400MHz,DMSO)δ8.16(s,2H),7.79(d,J=7.9Hz,2H),7.11(d,J=7.9Hz,4H),7.01(d,J=7.9Hz,2H),4.89(d,J=14.8Hz,1H),4.60(d,J=14.9Hz,1H),4.33(dd,J=7.2,4.9Hz,1H),3.57–3.51(m,1H),3.44(dd,J=14.9,7.0Hz,1H),2.44(s,1H),1.94(dd,J=11.8,4.1Hz,2H),1.72(dd,J=33.4,8.9Hz,6H),1.36(dd,J=20.5,9.4Hz,4H),1.30–1.14(m,2H).HRMS(ESI)calcd for C30H30N2O5BF5S(M+H+):637.1904;found 637.1967.
实施例3
(R)-(4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲基苯基)磺酰氨基)丙酰氨基)苯基)硼酸
步骤:将叔丁氧羰酰基肌氨酸换成BOC-D-丙氨酸,其余所需原料、试剂以及制备方法同实施例1,得白色固体。1H NMR(400MHz,DMSO)δ8.16(s,2H),7.81(d,J=8.0Hz,2H),7.11(dd,J=11.7,8.0Hz,4H),6.97(d,J=7.8Hz,2H),4.93(d,J=14.8Hz,1H),4.68(q,J=6.8Hz,1H),4.56(d,J=14.8Hz,1H),3.08(s,3H),2.47–2.38(m,1H),1.71(dd,J=28.2,9.4Hz,5H),1.43–1.25(m,5H),1.16(d,J=7.1Hz,3H).HRMS(ESI)calcd for C29H30N2O5BF5S(M+H+):625.1967;found 625.1943.
实施例4
(S)-(4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲基苯基)磺酰氨基)丙酰氨基)苯基)硼酸
步骤:将叔丁氧羰酰基肌氨酸换成N-叔丁氧羰基-L-丙氨酸,其余所需原料、试剂以及制备方法同实施例1,得白色固体。1H NMR(500MHz,DMSO)δ8.15(s,1H),7.81(d,J=7.5Hz,1H),7.16–7.04(m,4H),6.98(d,J=7.2Hz,2H),4.93(d,J=14.5Hz,1H),4.68(d,J=6.5Hz,1H),4.57(d,J=14.7Hz,1H),3.08(s,3H),2.44(s,1H),1.72(dd,J=34.1,8.8Hz,5H),1.35(t,J=9.4Hz,4H),1.18(t,J=11.3Hz,4H).HRMS(ESI)calcd for C29H30N2O5BF5S(M+H+):625.1967;found 625.1969.
实施例5
(R)-(4-(N-(4-环己基苄基)-1-((五氟苯基)磺酰基)氮杂环丁烷-2-甲酰胺基)苯基)硼酸
步骤:将叔丁氧羰酰基肌氨酸换成(R)-N-BOC-氮杂环丁烷-2-羧酸,其余所需原料、试剂以及制备方法同实施例1,得白色固体。1H NMR(500MHz,DMSO)δ8.13(s,2H),7.79(d,J=7.9Hz,2H),7.11(d,J=8.0Hz,2H),7.05(d,J=7.4Hz,4H),4.89(d,J=15.0Hz,1H),4.69(d,J=14.4Hz,2H),3.88(d,J=7.4Hz,2H),2.47–2.40(m,1H),2.32–2.22(m,1H),1.86(tt,J=7.5,3.9Hz,1H),1.71(dd,J=37.0,9.2Hz,5H),1.29(dt,J=38.0,7.6Hz,5H).HRMS(ESI)calcd for C29H28N2O5BF5S(M+H+):623.1812;found 623.1810.
实施例6
(4-(N-(4-环己基苄基)-2-((N,4-二甲基苯基)磺酰胺)乙酰胺)苯基)硼酸
步骤:将五氟苯磺酰氯换成对甲苯磺酰氯,其余所需原料、试剂以及制备方法同实施例1,得白色固体。1H NMR(400MHz,DMSO)δ8.15(s,1H),7.78(d,J=8.0Hz,2H),7.52(d,J=8.1Hz,2H),7.35(d,J=8.1Hz,2H),7.14(dd,J=11.6,8.2Hz,4H),7.05(d,J=7.8Hz,2H),4.77(s,2H),3.72(s,2H),2.78(s,3H),2.45(s,1H),2.37(s,3H),1.75(d,J=7.1Hz,4H),1.67(s,1H),1.35(t,J=10.8Hz,4H),1.24(s,1H).HRMS(ESI)calcd for C29H35N2O5BS(M+H+):535.2438;found 535.2446.
实施例7
(4-(2-((N,4-二甲基苯基)磺酰胺)乙酰胺)苯基)硼酸
步骤:将五氟苯磺酰氯换成对甲苯磺酰氯,其余所需原料、试剂以及制备方法同实施例1中的步骤1、3、4,得白色固体。1H NMR(400MHz,DMSO)δ10.03(s,1H),7.91(s,2H),7.74(s,1H),7.72(d,J=5.2Hz,2H),7.69(s,1H),7.51(d,J=8.2Hz,2H),7.44(d,J=8.0Hz,2H),3.90(s,2H),2.80(s,3H),2.41(s,3H).HRMS(ESI)calcd for C26H19N2O5BS(M+H+):363.1184;found 363.1184.
实施例8
(4-(3-(4-氰基苯基)-N-(4-环己基苄基)丙酰胺基)苯基)硼酸
具体制备过程为:
步骤1:制备3-(4-氰基苯基)-N-(4-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯基)丙胺(8a)
将4-氨基苯硼酸频哪醇酯(1.0g,4.57mmol)、4-氰基-3-苯基丙酸(0.96g,5.48mmol)、HATU(2.08g,5.48mmol)和N,N-二异丙基乙胺(2.4ml,13.71mmol)溶于适量的N,N-二甲基甲酰胺中,室温搅拌过夜。反应完成,乙酸乙酯以及水萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体1.49g,产率为86.5%。1H NMR(400MHz,DMSO)δ10.06(s,1H),7.76(d,J=8.2Hz,2H),7.59(s,4H),7.47(d,J=8.2Hz,2H),3.00(t,J=7.5Hz,2H),2.69(t,J=7.6Hz,2H),1.28(s,12H).LCMS:m/z(M+H+):376.20.
步骤2:制备3-(4-氰基苯基)-N-(4-环己基苄基)-N-(4-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯基)丙胺(8b)
/>
取氢化钠(0.3g,3.99mmol),加入适量的超干四氢呋喃,冰浴条件下缓慢加入化合物8a(0.5g,1.33mmol),搅拌1h,加入4-环己基苄溴(0.33g,1.33mmol),室温搅拌过夜。反应完成后,加水淬灭,乙酸乙酯萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体0.57g,产率为78.1%。1H NMR(500MHz,DMSO)δ7.69(d,J=7.5Hz,2H),7.61(d,J=7.4Hz,2H),7.31(d,J=7.6Hz,2H),7.06(dd,J=15.8,7.3Hz,4H),6.98(d,J=7.6Hz,2H),4.79(s,2H),2.89(t,J=7.2Hz,2H),2.41(d,J=10.8Hz,3H),1.77–1.66(m,5H),1.44–1.30(m,5H),1.26(s,12H).LCMS:m/z(M+H+):548.32.
步骤3:制备(4-(3-(4-氰基苯基)-N-(4-环己基苄基)丙酰胺基)苯基)硼酸
取化合物8b(0.37g,0.67mmol),加入适量的四氢呋喃和水溶解,加入高碘酸钠(0.43g,2.02mmol)和0.3ml 2M稀盐酸溶液,室温搅拌。反应完成后,用乙酸乙酯萃取,无水硫酸钠干燥,旋干溶剂得粗产品。柱层析得白色固体0.24g,产率为76.2%。1H NMR(400MHz,DMSO)δ8.09(s,2H),7.70(dd,J=13.1,8.1Hz,4H),7.30(d,J=8.0Hz,2H),7.09(d,J=8.0Hz,2H),6.99(d,J=7.8Hz,4H),4.79(s,2H),2.89(t,J=7.3Hz,2H),2.48–2.35(m,3H),1.71(dd,J=26.1,10.9Hz,5H),1.41–1.21(m,5H).HRMS(ESI)calcd for C29H31N2O3B(M+H+):467.2506;found 467.2447.
实施例9
(4-(N-(4-环己基苄基)-3-苯基丙酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成苯丙酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(400MHz,DMSO)δ7.74(d,J=7.9Hz,2H),7.21(t,J=7.3Hz,2H),7.14(t,J=7.1Hz,1H),7.08(t,J=10.4Hz,5H),7.04–6.98(m,3H),4.82(s,2H),2.83(t,J=7.5Hz,2H),2.40(d,J=22.1Hz,3H),1.70(dd,J=31.2,10.8Hz,5H),1.41–1.24(m,5H).HRMS(ESI)calcd for C28H32NO3B(M+H+):442.2553;found 442.2552.
实施例10
(4-((3r,5r,7r)-N-(4-环己基苄基)金刚烷-1-甲酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成1-金刚烷甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(400MHz,DMSO)δ8.12(s,2H),7.74(d,J=8.2Hz,2H),7.24–6.95(m,6H),4.69(s,2H),2.48–2.38(m,1H),1.90–1.57(m,15H),1.51(d,J=12.0Hz,3H),1.45–1.29(m,7H).HRMS(ESI)calcd for C30H38NO3B(M+H+):472.3023;found472.3028.
实施例11
(4-(2-((3r,5r,7r)-金刚烷-1-基)-N-(4-环己基苄基)乙酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成1-金刚烷乙酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ7.78(dd,J=23.4,7.7Hz,2H),7.07(dt,J=8.3,6.3Hz,6H),4.81(s,2H),2.47–2.39(m,1H),1.92(s,2H),1.85(s,3H),1.76–1.65(m,5H),1.61(d,J=11.8Hz,3H),1.53(d,J=12.2Hz,9H),1.36–1.16(m,5H).HRMS(ESI)calcd for C31H40NO3B(M+H+):486.3180;found 486.3183.
实施例12
(4-(N-(4-环己基苄基)-4-氟苯甲酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成对氟苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(400MHz,DMSO)δ7.60(t,J=7.5Hz,2H),7.39–7.35(m,2H),7.21–7.17(m,2H),7.12(t,J=7.0Hz,2H),7.02(dd,J=12.9,4.9Hz,4H),5.06(d,J=7.0Hz,2H),2.42(s,1H),1.75–1.64(m,5H),1.38–1.25(m,5H).HRMS(ESI)calcd forC26H27NO3BF(M+H+):432.2145;found 432.2158.
实施例13
(4-(N-(4-环己基苄基)-4-甲氧基苯甲酰氨基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成对甲氧基苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(400MHz,DMSO)δ7.61(d,J=8.3Hz,2H),7.30–7.25(m,2H),7.19(d,J=8.2Hz,2H),7.13(d,J=8.2Hz,2H),7.01(d,J=8.3Hz,2H),6.78–6.73(m,2H),5.06(s,2H),3.69(s,3H),2.43(d,J=2.5Hz,1H),1.76–1.65(m,5H),1.41–1.24(m,5H).HRMS(ESI)calcd for C27H30NO4B(M+H+):444.2345;found 444.2348.
实施例14
(4-(4-氰基-N-(4-环己基苄基)苯甲酰氨基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成对氰基苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ8.04(s,2H),7.69(d,J=8.0Hz,2H),7.62(d,J=7.9Hz,2H),7.50(d,J=7.9Hz,2H),7.21(d,J=7.8Hz,2H),7.14(d,J=7.8Hz,2H),7.06(d,J=7.6Hz,2H),5.09(s,2H),2.43(t,J=9.2Hz,1H),1.74–1.64(m,4H),1.38–1.17(m,6H).HRMS(ESI)calcd for C27H27N2O3B(M+H+):439.2192;found 439.2192.
实施例15
(4-(N-(4-环己基苄基)-2,4-二氟苯甲酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成2,4-二氟苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(400MHz,DMSO)δ7.57(dd,J=13.5,7.7Hz,2H),7.52–7.42(m,1H),7.22–7.06(m,5H),6.98(d,J=21.4Hz,3H),5.05(d,J=7.4Hz,2H),2.43(s,1H),1.70(dd,J=30.5,10.3Hz,5H),1.50–1.23(m,5H).HRMS(ESI)calcd for C26H26NO3BF2(M+H+):450.2051;found 450.2054.
实施例16
(4-(N-(4-环己基苄基)-2-苯基乙酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成苯乙酰氯,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ8.12(s,2H),7.79(d,J=7.9Hz,2H),7.25(t,J=7.3Hz,2H),7.19(t,J=7.2Hz,1H),7.16–7.05(m,8H),4.84(s,2H),3.47(s,2H),2.46–2.39(m,1H),1.77–1.65(m,5H),1.39–1.22(m,5H).HRMS(ESI)calcd for C27H30NO3B(M+H+):428.2396;found 428.2392.
实施例17
(4-(N-(4-环己基苄基)-2-苯氧基乙酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成苯氧乙酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ8.12(s,2H),7.80(d,J=8.1Hz,2H),7.29–7.27(m,2H),7.26–7.22(m,2H),7.12(d,J=2.5Hz,4H),6.92(t,J=7.3Hz,1H),6.77(d,J=8.0Hz,2H),4.86(s,2H),4.52(s,2H),2.44(dd,J=11.0,8.1Hz,1H),1.75(d,J=7.5Hz,3H),1.68(d,J=12.4Hz,1H),1.35(dd,J=12.7,8.9Hz,5H),1.25–1.19(m,1H).HRMS(ESI)calcd for C27H30NO4B(M+H+):444.2345;found 444.2345.
实施例18
(4-(N-(4-环己基苄基)-3,4-二氟苯甲酰氨基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成3,4-二氟苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ8.04(s,2H),7.62(d,J=8.3Hz,2H),7.44–7.37(m,1H),7.27(dt,J=10.4,8.4Hz,1H),7.20(d,J=8.1Hz,2H),7.13(d,J=8.1Hz,3H),7.06(d,J=8.2Hz,2H),5.06(s,2H),2.47–2.40(m,1H),1.76–1.65(m,5H),1.39–1.20(m,5H).HRMS(ESI)calcd for C26H26NO3BF2(M+H+):450.2051;found 450.2063.
实施例19
(4-(N-(4-环己基苄基)苯甲酰氨基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ8.00(s,2H),7.56(d,J=7.5Hz,2H),7.29(dd,J=19.1,7.4Hz,3H),7.21(dd,J=14.2,7.3Hz,4H),7.14(d,J=7.7Hz,2H),7.01(d,J=7.6Hz,2H),5.07(s,2H),2.44(s,1H),1.75(s,4H),1.68(d,J=12.7Hz,1H),1.42–1.30(m,4H),1.24(s,1H).HRMS(ESI)calcd for C26H28NO3B(M+H+):414.2240;found 414.2244.
实施例20
(4-(N-(4-环己基苄基)-2-(苯硫基)乙酰胺)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成苯硫基乙酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(500MHz,DMSO)δ8.11(s,1H),7.77(d,J=8.0Hz,1H),7.31–7.22(m,4H),7.18(dd,J=16.8,7.5Hz,3H),7.09(dd,J=23.3,7.8Hz,4H),4.84(s,2H),3.68(s,2H),2.48–2.37(m,1H),1.82–1.63(m,5H),1.41–1.28(m,4H),1.21(dd,J=15.0,6.0Hz,1H).HRMS(ESI)calcd for C27H30NO3BS(M+H+):460.2117;found 460.2117.
实施例21
(4-(N-(4-环己基苄基)-4-苯氧基苯甲酰胺基)苯基)硼酸
步骤:将4-氰基-3-苯基丙酸换成4-苯氧基苯甲酸,其余所需原料、试剂以及制备方法同实施例8,得白色固体。1H NMR(400MHz,DMSO)δ8.01(s,2H),7.60(d,J=8.2Hz,2H),7.41(d,J=7.6Hz,2H),7.32(d,J=8.7Hz,2H),7.19(d,J=8.2Hz,3H),7.14(d,J=8.1Hz,2H),7.00(dd,J=13.4,8.0Hz,4H),6.80(d,J=8.7Hz,2H),5.07(s,2H),2.45(s,1H),1.75(d,J=9.0Hz,4H),1.67(s,1H),1.35(t,J=10.0Hz,5H).HRMS(ESI)calcd for C32H32NO4B(M+H+):506.2503;found 506.2502.
实施例22
(4-(4-苯氧基苯甲胺)苯基硼酸
/>
步骤:将叔丁氧羰酰基肌氨酸换成4-苯氧基苯甲酸,其余所需原料、试剂以及制备方法同实施例8中的步骤1和步骤3,得白色固体。1H NMR(400MHz,DMSO)δ10.22(s,1H),8.01(d,J=8.4Hz,2H),7.95(s,2H),7.76(q,J=8.0Hz,4H),7.46(t,J=7.6Hz,2H),7.23(t,J=7.2Hz,1H),7.11(t,J=7.8Hz,4H).HRMS(ESI)calcd for C19H16NO4B(M+H+):334.1249;found334.1249.
实施例23
(4-(4-环己基苯甲酰胺)苯基硼酸
步骤:将叔丁氧羰酰基肌氨酸换成4-环己基苯甲酸,其余所需原料、试剂以及制备方法同实施例8中的步骤1和步骤3,得白色固体。1H NMR(400MHz,DMSO)δ10.18(s,1H),7.94(s,2H),7.88(d,J=8.2Hz,2H),7.76(d,J=3.4Hz,4H),7.37(d,J=8.2Hz,2H),2.58(t,J=10.9Hz,1H),1.80(d,J=10.3Hz,4H),1.71(d,J=12.5Hz,1H),1.41(dd,J=25.7,11.9Hz,4H),1.25(d,J=12.6Hz,1H).HRMS(ESI)calcd for C19H22NO3B(M+H+):324.1780;found324.1780.
实施例24
3-(N-(4-环己基苄基)-2-((N,4-二甲基苯基)磺酰胺基)乙酰氨基)苯基)硼酸
步骤:将4-氨基苯硼酸频哪醇酯换成3-氨基苯硼酸频哪醇酯,其余所需原料、试剂以及制备方法同实施例6,得白色固体。1H NMR(500MHz,DMSO)δ8.19(s,2H),7.74(d,J=6.7Hz,1H),7.61(s,1H),7.52(d,J=7.7Hz,2H),7.36(dd,J=17.2,7.9Hz,3H),7.20(d,J=7.7Hz,1H),7.13(d,J=7.6Hz,2H),7.05(d,J=7.6Hz,2H),4.76(s,2H),3.68(s,2H),2.77(s,3H),2.45(s,1H),2.37(s,3H),1.79–1.74(m,4H),1.69(d,J=12.6Hz,1H),1.36(t,J=11.4Hz,4H),1.30(s,1H).HRMS(ESI)calcd for C29H35N2O5BS(M+H+):535.2438;found535.2436.
实施例25
(3-(4-苯氧基苯甲胺)苯基硼酸
步骤:将4-氨基苯硼酸频哪醇酯换成3-氨基苯硼酸频哪醇酯,其余所需原料、试剂以及制备方法同实施例22,得白色固体。1H NMR(500MHz,DMSO)δ10.15(s,1H),8.04(t,J=8.5Hz,5H),7.84(d,J=8.0Hz,1H),7.55(d,J=7.3Hz,1H),7.45(d,J=7.8Hz,2H),7.32(t,J=7.7Hz,1H),7.22(d,J=7.4Hz,1H),7.11(dd,J=13.8,8.3Hz,4H).HRMS(ESI)calcd forC19H16NO4B(M+H+):334.1249;found 334.1249.
实施例26
(3-(N-(4-环己基苄基)-4-苯氧基苯甲酰氨基)苯基)硼酸
步骤:将4-氨基苯硼酸频哪醇酯换成3-氨基苯硼酸频哪醇酯,其余所需原料、试剂以及制备方法同实施例21,得白色固体。1H NMR(400MHz,DMSO)δ8.04(s,2H),7.53(d,J=5.8Hz,2H),7.39(t,J=7.8Hz,2H),7.30(d,J=8.5Hz,2H),7.19(t,J=7.4Hz,3H),7.15(d,J=7.9Hz,3H),7.05(d,J=7.8Hz,1H),6.95(d,J=8.0Hz,2H),6.79(d,J=8.6Hz,2H),5.06(s,2H),2.45(s,1H),1.76(s,4H),1.70(s,1H),1.35(t,J=10.5Hz,4H),1.24(s,1H).HRMS(ESI)calcd for C32H32NO4B(M+H+):506.2503;found 506.2503.
生物活性部分
实施例1~26制备得到的硼酸化合物分别记为化合物1~26。
研究发现,与阳性对照化合物SH-4-54相比,硼酸化合物能够显著有效抑制STAT3的表达水平,进而抑制癌细胞的增殖、生存、迁移和侵袭并促进其凋亡。
应用例1硼酸化合物抑制胃癌细胞增殖、生存、迁移和侵袭并促进其凋亡
(1)抑制胃癌细胞增殖
采用CCK8法检测细胞活力来检测化合物对胃癌细胞增殖的影响。实验方法如下:取对数生长期的细胞,以(1.5~3)×103cells/孔,100μL/孔的细胞密度接种于96孔板中,培养12~24h后,设置不加化合物对照组、空白组和化合物组。不加药对照组细胞,只加等体积培养基;空白组不加细胞,也不加化合物,只加培养基;化合物组细胞加入不同浓度的小分子化合物,继续培养72h,然后往96孔板中避光加入10μL/孔的CCK8检测试剂,37℃避光孵育1~4h,用酶标仪检测450nm波长下的吸光度值(OD)。实验独立重复三次。细胞活力(%)=[OD(加药)-OD(空白)]/[OD(对照)-OD(空白)]×100%。最后用GraphPad Prism 8软件进行非线性回归得到对应的半数抑制浓度(IC50),结果如表1所示。与羧酸类阳性对照化合物SH-4-54相比,化合物1-5抑制胃癌细胞增殖的能力有明显的优势。因此,根据活性结果,选取抑制效果最佳的化合物1进行后续的生物活性研究。
表1化合物对胃癌细胞的抑制活性
(2)化合物1对胃癌细胞克隆形成的影响
取对数生长期的细胞,以400~600cells/孔接种于6孔板中,置于37℃,5%CO2细胞培养箱中,培养24h至细胞贴壁后,加入不同浓度的化合物1和阳性对照药物SH-4-54,继续培养两周,其间每2~3天换一次含有化合物的培养基。两周后,吸去培养基,加入PBS洗涤,重复洗涤两次,弃去PBS。加入4%多聚甲醛,室温固定15min,弃去固定液,加入PBS洗涤两次,弃去PBS。加入1mL结晶紫染色液,避光孵育30min,弃去结晶紫。加入PBS洗涤至背景变干净,室温晾干。然后拍照并统计每孔集落数,利用GraphPad Prism软件进行统计学分析,实验独立重复3次。
结果如图1所示,图1(A)结果表示化合物1在0.5μM和1μM时能够明显抑制AGS细胞的克隆形成,在1μM和3μM时能够明显抑制MGC803细胞的生长,且在两株胃癌细胞上抑制克隆形成的效果均比羧酸类阳性对照化合物SH-4-54强。图1(B)为图1(A)的统计结果图,表示化合物1能够显著抑制胃癌细胞的克隆形成,且与对照药SH-4-54相比,有统计学差异。
(3)化合物1能够明显抑制胃癌细胞的迁移
取对数生长期的细胞,接种于6孔板中,于培养箱中培养24h,待细胞贴壁并生长至汇合度约90%时,用枪头比着直尺划痕,弃去培养基,用PBS洗2次,加入新鲜培养基,显微镜下拍照,设置对照组和化合物组,对照组不加化合物,化合物组加入不同浓度化合物1和SH-4-54,置于37℃、5%CO2培养箱培养24h。然后弃去培养基,加入PBS洗两次,弃去PBS,加入培养基,拍照并统计化合物处理24h后细胞迁移的程度,实验独立重复3次。
实验结果如图2所示,图2(A)表示划痕实验检测化合物对胃癌细胞迁移的影响,与对照组相比,化合物1能够显著抑制胃癌细胞的迁移,且与阳性对照药SH-4-54相比,硼酸类化合物1具有更显著的抑制胃癌细胞迁移的效果。图2(B)为图2(A)的统计结果图,显示在抑制胃癌细胞迁移方面,化合物1的优势效果与SH-4-54相比具有统计学差异。
(4)化合物1能够显著抑制胃癌细胞的侵袭
在Transwell小室中取出嵌套至另一新的24孔板,加入空白培养基浸泡,室温浸泡1h以上,进行嵌套活化。取对数生长期的胃癌细胞,用含10%FBS重悬细胞,在24孔板小室下层加入500μL含10%FBS的培养基,嵌套小室上层加入(1~2)×104cells/孔,300μL/孔细胞悬液,于培养箱中培养12~24h至细胞贴壁。然后小室底部换成含20%FBS的培养基,嵌套上层将培养基换成含有或不含有化合物的2%FBS的培养基,于培养箱中继续培养24h。24h后,弃去培养基,用PBS洗一次,弃去PBS。在嵌套上下层均加入500μL 4%多聚甲醛固定液,室温固定15min,弃去固定液。加入PBS洗一次,弃去PBS。在嵌套上下层均加入结晶紫染色液,室温避光染色30min,弃去结晶紫染色液。加入PBS洗至背景变干净,室温自然晾干小室。然后进行拍照观察并统计各浓度下穿过Transwell嵌套膜的细胞数,实验独立重复3次。
实验结果如图3所示,图3(A)为显微镜拍照下各化合物浓度下侵袭细胞图,结果显示,经化合物1和SH-4-54处理后,侵袭细胞变少,说明化合物1和SH-4-54均能够显著抑制胃癌细胞的侵袭,但是与SH-4-54相比,硼酸类化合物1具有更明显的抑制胃癌细胞侵袭的效果,说明硼酸类化合物比羧酸类化合物更能抑制胃癌细胞侵袭;图3(B)为图3(A)的统计结果图,结果显示化合物1比SH-4-54更能抑制胃癌细胞的侵袭,具有统计学差异。
(5)化合物1能够促进胃癌细胞凋亡
采用Annexin V-FITC/PI双染法检测化合物1促进胃癌细胞凋亡的能力。取对数生长期的胃癌细胞,接种于6孔板中,于培养箱中培养24h至细胞贴壁,设置对照组和化合物组,对照组不加药,化合物组加入不同浓度的化合物1或SH-4-54,继续培养72h后,利用贝博的Annexin V-FITC/PI双染细胞凋亡检测试剂盒(BB-4101-1)进行检测。弃去6孔板中的培养基,加入PBS洗2次,利用不含EDTA的胰酶消化,收集并离心,用预冷的PBS洗2次,加入400μL 1×Annexin V结合液重悬细胞,加入5μL Annexin V-FITC染色液,轻轻混匀,于冰上避光孵育15min。然后加入10μL PI染色液后轻轻混匀,于冰上避光孵育5min。然后立即用流式细胞仪进行检测。
实验结果如图4所示,图4(A)为利用流式细胞仪检测胃癌细胞凋亡的情况,如图所示,与对照组和化合物SH-4-54组相比,化合物1处理72h后能够明显促进胃癌细胞的凋亡,且在相同浓度下,化合物1促进胃癌细胞凋亡的效果明显比SH-4-54化合物好;图4(B)为图4(A)的统计图,结果显示,化合物1促进胃癌细胞凋亡的效果优于SH-4-54,具有统计学差异。
应用例2硼酸类化合物抑制胃癌细胞生长的机制
本应用例以化合物1为例,说明本发明硼酸类化合物抑制胃癌细胞生长的机制
(1)化合物1能够与STAT3蛋白结合
SPR验证化合物与STAT3蛋白结合:将STAT3蛋白冰上融解后低温超滤,用PBS将蛋白配置成100μg/mL浓度,通过氨基耦联的方式锚定到CM5芯片上,化合物1和化合物SH-4-54分别溶于经0.22μm滤膜过滤后的含1%DMSO的PBS缓冲液中,然后倍半稀释得到不同化合物浓度(含有1%DMSO)。将不同浓度的化合物由低到高依次通过芯片,得到响应信号,通过软件计算动力学和亲和力,确定结合亲和度(KD)。
细胞热转移(CETSA)实验验证化合物与细胞内的STAT3蛋白结合:将对数生长期的胃癌细胞MGC803接种于15cm大皿中,于培养箱中培养24h,待细胞贴壁生长至汇合度70%~80%时,分别加入化合物1和SH-4-54,使其终浓度为5μM,继续培养3h后收板。吸去培养基,加入PBS洗涤一次,经过胰酶消化、培养基终止消化、离心后,弃去上清,加入PBS洗涤2次,离心弃去PBS。分别加入1mL PBS(含1%磷酸酶抑制剂和1%PMSF)重悬细胞,将细胞悬液分装于PCR管中,然后置于梯度PCR仪中,在不同温度下加热2min,室温静置3min,然后样品立即放入液氮中冷冻。为了使细胞溶解释放蛋白,需要将样品在液氮中冷冻,然后室温解冻,反复冻融3次。然后4℃,20000×g离心20min。取上清,加入5×Loading Buffer,100℃,煮沸5min。然后用聚丙烯酰胺凝胶SDS-PAGE电泳分离蛋白样品,通过湿转的方法将蛋白转移至硝酸纤维素薄膜(PVDF膜)上,经5%BSA封闭1h后,分别用pY705-STAT3、T-STAT3、c-Myc、Bcl-XL和β-Actin的一抗在4℃下孵育过夜,再分别用带有荧光标记的兔二抗、鼠二抗室温孵育1h,ECL化学发光液避光孵育2min,最后用Bio-RAD显影仪检测蛋白的表达水平。
实验结果如图5所示,图5(A)SPR结果显示,化合物1在体外能够与STAT3蛋白有明显的结合,而且与SH-4-54相比,化合物1具有更高的结合活性。图5(B)CESTA结果显示,化合物1能够进入癌细胞并与细胞内的STAT3蛋白结合,且与对照药SH-4-54相比,化合物1与胃癌细胞内的STAT3蛋白结合活性更高。这些写过说明本发明的硼酸类化合物可以与STAT3蛋白结合,并且结合活性比对照化合物SH-4-54更高。
(2)化合物1可以抑制pY705-STAT3的磷酸化及下游基因的表达
收集已经过化合物1或SH-4-54处理的细胞,弃去培养基,用PBS洗两次,加入裂解液(RIPA:PMSF:phosphatase A:phosphatase B=100:1:1:1),冰上振荡裂解15min,用细胞刮将细胞裂解物刮下,将细胞板斜躺于冰上,静置5min,将细胞裂解物转移到EP管中,然后4℃,15000rpm离心15min,取上清进行蛋白定量,加入5×Loading Buffer,100℃煮沸5min。然后蛋白质免疫印记(Western Blot)方法进行检测,首先用聚丙烯酰胺凝胶SDS-PAGE电泳分离蛋白样品,通过湿转的方法将蛋白转移至硝酸纤维素薄膜(PVDF膜)上,经5%BSA封闭1h后,分别用pY705-STAT3、T-STAT3、c-Myc、Bcl-XL和β-Actin的一抗在4℃下孵育过夜,再分别用带有荧光标记的兔二抗、鼠二抗室温孵育1h,ECL化学发光液避光孵育2min,最后用Bio-RAD显影仪检测蛋白的表达水平。
实验结果如图6所示,经化合物1处理后,胃癌细胞中pY705-STAT3的磷酸化水平和下游基因c-Myc、Bcl-XL的表达水平均明显下降,且与对照化合物SH-4-54相比,化合物1抑制STAT3信号通路的效果更明显。说明硼酸类化合物在抑制胃癌细胞内STAT3信号通路的效果优于SH-4-54。
(3)化合物1抑制STAT3的转录活性
293T细胞培养于含10%胎牛血清的DMEM中,取对数生长期的细胞消化,计数,将细胞以1~2×104cells/100μL密度接种于96孔板中,将细胞培养于5%CO2,37℃培养箱中,待细胞贴壁长到汇合度70%~80%时,进行细胞转染。分别在无菌1.5mL EP管中配制A、B两种混合溶液(以下为每一孔的用量:A:0.25μL Lipo 2000+OPTI-MEMI培养基,体积为5μL;B:50ng pGL3-STAT3-promoter质粒+50ng STAT3C质粒+40ng TKRL(海肾萤光素报告基因质粒)+OPTI-MEM培养基,体积为5μL),轻轻混匀,静置5min,再将A溶液转移到B管中,轻轻混匀,室温静置15min。用移液枪将10μL配制好的转染液滴加至96孔板中,置于细胞培养箱中继续培养。转染24h后,加入不同浓度的1或SH-4-54化合物继续处理24h。将萤火虫萤光素酶检测试剂和海肾萤光素酶检测缓冲液融解至室温,海肾萤光素酶检测底物(100×)置于冰浴上备用;按照每孔25μL用量,取适量海肾萤光素酶检测缓冲液,按照1:100加入海肾萤光素酶检测底物(100×)配制成海肾萤光素酶检测工作液;取出96孔板,弃去培养基,每孔加入50μL报告基因细胞裂解液,震荡混匀10min;取25μL裂解液至96孔白板中,每孔再加入25μL萤火虫萤光素酶检测试剂,震荡混匀5min,检测得到RLU1;在完成上述测定萤火虫萤光素酶步骤后,每孔加入25μL海肾萤光素酶检测工作液,震荡混匀5min,检测得到RLU2;得到RLU1/RLU2的比值。
实验结果如图7所示,经硼酸类化合物1处理后,STAT3的转录活性明显受到抑制,且与对照化合物SH-4-54对比,化合物1抑制STAT3转录活性的效果更明显,说明硼酸类化合物抑制STAT3信号转录活性优于SH-4-54。
(4)化合物1抑制STAT3二聚化
利用免疫共沉淀(Co-IP)的方法检测STAT3的二聚化。293T细胞培养于含10%胎牛血清的DMEM中,取对数生长期的293T细胞接种于6孔板中,培养12~24h待细胞贴壁生长至汇合度约为70%~80%时,进行细胞转染。分别在无菌1.5mL EP管中配制A、B两种混合溶液(以下为每一孔的用量:A:4μL Lipo 2000+OPTI-MEMI培养基,体积为100μL;B:2.5μg HA-STAT3质粒+2.5μg Flag-STAT3质粒+OPTI-MEM培养基,体积为100μL),轻轻混匀,静置5min,再将A溶液转移到B管中,轻轻混匀,室温静置15min。取出6孔板,吸去旧的培养基,加入800μL OPTI-MEMI培养基,用移液枪将200μL配制好的转染液滴加至6孔板中,置于细胞培养箱中继续培养,转染6h后将6孔板中的培养基换成含10%FBS的DMEM培养基,继续培养。转染24h后加入不同浓度的化合物1,继续培养24h。
药物处理24h后,在收取蛋白的前1h加入终浓度为100ng/mL的IL-6刺激,然后提取细胞的总蛋白,收集已经过化合物1或SH-4-54处理的细胞,弃去培养基,用PBS洗两次,加入IP裂解液(RIPA:PMSF:phosphatase A:phosphatase B=100:1:1:1),冰上振荡裂解15min,用细胞刮将细胞裂解物刮下,将细胞板斜躺于冰上,静置5min,将细胞裂解物转移到EP管中,然后4℃,15000rpm离心15min,取上清进行蛋白定量,在不同EP管中分别吸取相同蛋白总量的不同处理的样品。取带有Flag抗体的免疫共沉淀的Beads,用PBST洗两遍,4℃,5000rpm离心30s,加入适量的PBS重悬。将Beads均分到装有相同蛋白量的EP管中,轻轻混匀,放入4℃冰箱旋转摇床中翻转过夜。过夜翻转后,5000rpm离心30s,弃上清,往沉淀中加入500μL PBST,旋转5min,5000rpm离心30s,重复洗2遍。往沉淀中加入2×Loading Buffer,煮沸5min。接下来用蛋白质免疫印记(Western Blot)检测STAT3的二聚化,首先用聚丙烯酰胺凝胶SDS-PAGE电泳分离蛋白样品,通过湿转的方法将蛋白转移至硝酸纤维素薄膜(PVDF膜)上,经5%BSA封闭1h后,分别用HA、Flag和β-Actin的一抗在4℃下孵育过夜,再分别用带有荧光标记的兔二抗、鼠二抗室温孵育1h,ECL化学发光液避光孵育2min,最后用Bio-RAD显影仪检测蛋白的表达水平。
实验结果如图8所示,经硼酸类化合物1处理后,细胞内HA-STAT3和Flag-STAT3蛋白的结合显著减少,且具有浓度依赖性。说明化合物1可以减少STAT3蛋白的二聚化。
应用例3硼酸类化合物在动物整体模型上的药效、药理和毒理研究
本应用例以化合物1为例,说明本发明硼酸类化合物在动物整体模型上的药效、药理和毒理研究。
取对数生长期的MGC803细胞,消化离心后计数,用预冷的PBS洗2遍,将预冷PBS与Matrigel按照1:1的比例重悬细胞,配成2×106cells/100μL浓度,置于冰上。分别在裸鼠的腹背两侧皮下注射100μL细胞悬液,待肿瘤体积达到70mm3左右时,开始分组给药;将裸鼠随机分成4组,溶剂对照组腹腔注射等量溶剂(含15%蓖麻油的灭菌PBS溶液),低剂量组腹腔注射5mg/kg的化合物1,高剂量组腹腔注射15mg/kg的化合物1,阳性对照组腹腔注射15mg/kg的SH-4-54,连续给药21天。每两天用游标卡尺和电子秤分别测量肿瘤体积大小和小鼠体重。给药21天后,处死小鼠进行解剖,取出肿瘤和心、肝、脾、肺、肾等脏器进行后续实验。
实验结果如图9所示,图(9A)肿瘤图显示,经化合物1和对照化合物SH-4-54治疗21天后,与未治疗相比,小鼠的肿瘤明显较小,说明化合物1和SH-4-54均能够抑制小鼠肿瘤生长。但是化合物1在低剂量5mg/kg时就已经有明显的抑制肿瘤生长的作用,并且比对照化合物SH-4-54在高剂量15mg/kg的抑制效果还明显,说明化合物1抑制体内肿瘤生长的效果优于SH-4-54。图(9B)图(9C)分别为肿瘤的生长曲线图和重点肿瘤重量统计图,也可以得到同样的验证,化合物1抑制肿瘤生长的效果优于SH-4-54。进一步在肿瘤组织中验证化合物1和SH-4-54抑制肿瘤生长的机制,图(9D)Western Blot结果显示,化合物1能够抑制肿瘤组织中pY705-STAT3的磷酸化水平和下游与肿瘤生长相关的c-Myc和Bcl-xL的表达,且抑制效果优于对照化合物SH-4-54。对化合物的毒性探究发现,从图(9E)小鼠重量生长统计图中可以看出,与溶剂组相比,化合物1和SH-4-54对小鼠的生长并没有明显影响;从图(9F)可以看出,化合物1和SH-454对主要脏器形态基本没有影响,说明化合物1抑制肿瘤生长的同时对小鼠的整体毒性较小。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,对于本领域的普通技术人员来说,在上述说明及思路的基础上还可以做出其它不同形式的变化或变动,这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明权利要求的保护范围之内。
Claims (4)
1.一种硼酸化合物,其特征在于,具有如式(Ⅰ)所示结构:
式(Ⅰ)选自如下结构:
2.权利要求1所述硼酸化合物的制备方法,其特征在于,包括如下步骤:
S1:将式(1)所示相应的胺和式(2)所示相应的酸溶于溶剂中,经缩合反应后生成式(3)所示中间体;
S2:式(3)所示中间体与式(4)所示物质在碱性条件下经取代反应得到式(5)所示中间体;
S3:式(5)所示中间体在酸性条件下水解,即得式(Ⅰ)所述硼酸化合物;
3.权利要求1所述硼酸化合物及其药学可接受的盐在制备抑制STAT3活性的药物中的用途。
4.权利要求1所述硼酸化合物及其药学可接受的盐在制备预防和/或***的药物中的用途,所述肿瘤为胃癌。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210228962.7A CN114751927B (zh) | 2022-03-08 | 2022-03-08 | 一种硼酸化合物、制备方法及用途 |
PCT/CN2022/099680 WO2023168851A1 (zh) | 2022-03-08 | 2022-06-20 | 一种硼酸化合物、制备方法及用途 |
PCT/CN2022/124702 WO2023168940A1 (zh) | 2022-03-08 | 2022-10-11 | ZnAl2O4在颜料中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210228962.7A CN114751927B (zh) | 2022-03-08 | 2022-03-08 | 一种硼酸化合物、制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114751927A CN114751927A (zh) | 2022-07-15 |
CN114751927B true CN114751927B (zh) | 2023-10-31 |
Family
ID=82325535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210228962.7A Active CN114751927B (zh) | 2022-03-08 | 2022-03-08 | 一种硼酸化合物、制备方法及用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114751927B (zh) |
WO (2) | WO2023168851A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CN105120854A (zh) * | 2012-05-25 | 2015-12-02 | 多伦多大学管理委员会 | 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
WO2018156901A1 (en) * | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2020117877A1 (en) * | 2018-12-04 | 2020-06-11 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
CN111601810A (zh) * | 2018-01-15 | 2020-08-28 | 爱杜西亚药品有限公司 | 吲哚胺2,3-双加氧酶和/或色氨酸2,3-双加氧酶的抑制剂 |
WO2021178907A1 (en) * | 2020-03-05 | 2021-09-10 | Janpix, Ltd. | Stat inhibitory compounds and compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA430866A (en) * | 1945-10-30 | Edward Barton Louis | Zinc aluminate pigment and paint | |
US2269508A (en) * | 1939-03-16 | 1942-01-13 | Louis E Barton | Zinc aluminate pigment and paint and method of making same |
JPH06191838A (ja) * | 1992-10-30 | 1994-07-12 | Dainichiseika Color & Chem Mfg Co Ltd | 新規体質顔料及び顔料組成物 |
JPH11100530A (ja) * | 1997-09-29 | 1999-04-13 | Nisshin Steel Co Ltd | 光反射性塗料組成物および塗装製品 |
US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
EP2534156A1 (en) * | 2010-02-11 | 2012-12-19 | OSI Pharmaceuticals, LLC | 7-aminofuropyridine derivatives |
SG11202105345TA (en) * | 2018-11-21 | 2021-06-29 | Univ Case Western Reserve | Compositions and methods of modulating short-chain dehydrogenase activity |
-
2022
- 2022-03-08 CN CN202210228962.7A patent/CN114751927B/zh active Active
- 2022-06-20 WO PCT/CN2022/099680 patent/WO2023168851A1/zh unknown
- 2022-10-11 WO PCT/CN2022/124702 patent/WO2023168940A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CN105120854A (zh) * | 2012-05-25 | 2015-12-02 | 多伦多大学管理委员会 | 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
WO2018156901A1 (en) * | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
CN111601810A (zh) * | 2018-01-15 | 2020-08-28 | 爱杜西亚药品有限公司 | 吲哚胺2,3-双加氧酶和/或色氨酸2,3-双加氧酶的抑制剂 |
WO2020117877A1 (en) * | 2018-12-04 | 2020-06-11 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
WO2021178907A1 (en) * | 2020-03-05 | 2021-09-10 | Janpix, Ltd. | Stat inhibitory compounds and compositions |
Non-Patent Citations (5)
Title |
---|
"A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET";Jing Li等;《Biochemical Pharmacology》;第190卷(第114620期);第1-15页 * |
"Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3";Lin Deng等;《J. Med. Chem.》;第65卷;第13094-13111页 * |
"Glycan-Directed Grafting-from Polymerization of Immunoglobulin G: Site-Selectively Modified IgG−Polymer Conjugates with Preserved Biological Activity";Chih-Hung Chou等;《Biomacromolecules》;第19卷;第3086-3095页 * |
"Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity";Antonella Messore等;《J. Med. Chem.》;第61卷;第10834-10859页 * |
"registry".《STN》.第1-20页. * |
Also Published As
Publication number | Publication date |
---|---|
WO2023168940A1 (zh) | 2023-09-14 |
WO2023168851A1 (zh) | 2023-09-14 |
CN114751927A (zh) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11337956B2 (en) | IRE-1α inhibitors | |
KR20040023616A (ko) | Hiv 프로테아제 억제제, 이를 함유하는 조성물, 그의약학적 용도 및 그의 합성을 위한 물질 | |
JP7511557B2 (ja) | ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途 | |
CN112300153B (zh) | 一种杂环化合物、药物组合物和用途 | |
WO2013060179A1 (zh) | 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法 | |
WO2021088265A1 (zh) | 咪唑并吡啶类化合物、包含该化合物的药物组合物及其制备方法和用途 | |
WO2021052501A1 (zh) | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 | |
Ding et al. | Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure | |
Yan et al. | Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site | |
CN107721975A (zh) | 具有抗肿瘤活性的brd4小分子抑制剂、合成方法及其应用 | |
CN114751927B (zh) | 一种硼酸化合物、制备方法及用途 | |
CN108358894B (zh) | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 | |
CN114702509B (zh) | 一种苯并噻吩并萘酰亚胺衍生物及其合成工艺和应用 | |
CN109081818B (zh) | 新型吲哚胺2,3-双加氧化酶抑制剂 | |
CN113444074B (zh) | 一种具有EGFR和Wnt双重抑制作用的化合物及其制备方法和应用 | |
CN113620943B (zh) | 硝基呋喃类化合物、药物组合物及其制备方法和用途 | |
CN107163028A (zh) | 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用 | |
CN108947904B (zh) | 一种含有七元内酰胺环的化合物及其应用 | |
CN111943947A (zh) | 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用 | |
Xu et al. | Discovery of second generation heat shock protein 110 (HSP110) inhibitors for potential treatment of Colorectal cancer | |
CN113831346B (zh) | 多靶点抗肿瘤小分子及其衍生物、制法、药物组合物和应用 | |
CN116332802B (zh) | 一种微管蛋白和nrp1双靶点化合物及其制法与应用 | |
CN115215799B (zh) | 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用 | |
CN111875606B (zh) | 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用 | |
WO2021092892A1 (zh) | 喹啉或喹唑啉类化合物在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |